Certain methylenediphenyl diisocyanate and diamine (MDI/MDA) substances are among those identified as priorities for action for the second phase of the Chemicals Management Plan (CMP). The selection of these MDI/MDA substances for action is based on the categorization process completed in 2006 and on new information received as part of the first phase of the CMP. Polymeric MDA was not initially prioritized for screening assessment but was added to the MDI/MDA Substance Grouping, because of its similarity to the other MDA substance in the Grouping.
|Group of Substances||CAS RN||Chemical Substance||Draft Screening Assessment||Proposed Risk Management Scope|
|9016-87-9||Isocyanic acid, polymethylenepolyphenylene ester|
|25214-70-4||Formaldehyde, polymer with benzenamine|
|If needed, information gathering tools could be used to inform potential risk management actions.|
|Fall 2015||Anticipated publication in Canada Gazette of the final screening assessment decisions under subsection 77(6) of CEPA 1999, release of Government's proposed risk management approach document on MDIs and start of 60-day public comment period on the proposed risk management approach document.|
|August 16, 2014||Publication in Canada Gazette and start of 60-day public comment period on (a) the draft screening assessment and (b) the risk management scope document on MDI substances.|
|December 17, 2012||Deadline for submission of any voluntary information by interested stakeholders.|
|October 16, 2012||Deadline for submission of information for the section 71 Notice (without an extension).|
|June 16, 2012||Release of the section 71 Notice with respect to certain MDI/MDA substances and the accompanying technical documents.|
In August 2014, the draft screening assessment was released and the related Notice was published in the Canada Gazette, Part I: Vol. 148, No. 33 - August 16, 2014 ( PDF Version - 937 K). This draft screening assessment addresses seven substances in the MDI/MDA Substance Grouping; two MDA substances and five MDI substances. The five MDI substances include three monomeric substances, one polymeric MDI substance, and one mixed MDI substance. The draft screening assessment proposes to conclude that two MDA substances are not harmful to the environment or to human health. It also proposes to conclude that five MDI substances are harmful to human health as set out in section 64(c) of the Canadian Environmental Protection Act, 1999 (CEPA 1999). A risk management scope document was also released in conjunction with this publication. There is a 60-day public comment period associated with these publications.
In June 2012, a Notice was issued in the Canada Gazette, Part I: Vol.146, No.24 - June 16, 2012 ( PDF Version - 3,671 K) under section 71 of the Canadian Environmental Protection Act, 1999 (CEPA 1999). This Notice applies to 8 substances; specifically, 7 substances which are part of the Methylenediphenyl Diisocyanate and Diamine (MDI/MDA) Substance Grouping, and one substance (phenol, methyl-) which is part of the Internationally Classified Substance Grouping. Given similar data needs among the two substance groupings, the data requests were combined in this Notice. Every person to whom this Notice applied was required to comply with the Notice no later than 5 p.m. EDT, October 16, 2012.
It is important to note that polymeric MDA (CAS RN 25214-70-4), included in the Notice, was not identified in the MDI/MDA Substance Grouping. However information was collected on this CAS RN as it was believed to be a commercially relevant mixture containing 4,4-MDA (CAS RN 101-77-9).
In October 2011, an announcement was published in the Canada Gazette, Part I: Vol. 145 No. 41 - October 8, 2011 regarding planned actions to assess and manage, where appropriate, the risk posed by certain substances to the health of Canadians and the environment. This initiative builds on the first phase of the Chemicals Management Plan (CMP) by identifying approximately 500 substances, in nine substance groupings, as priorities for the second phase of the CMP. These substances will be assessed over the coming five years.
If you have questions or comments, please Contact us. Indicate on the envelope or subject line "CMP MDI/MDA Substance Grouping".